TrialClinical cancer research : an official journal of the American Association for Cancer Research2022

Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002).

Xin Hua et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.